Examkin

Question

Difficulty: Very hardPharmacologic Interventions

A 34-year-old woman is evaluated in the emergency department for a two-day history of progressive left leg swelling and pain. She has a known medical history of an ischemic stroke at age 28 and three spontaneous consecutive first-trimester abortions, for which she was extensively evaluated. Outpatient serologic testing at that time confirmed high titers of anti-cardiolipin IgG, anti-beta-2-glycoprotein I IgG, and a repeatedly positive lupus anticoagulant. Her only current medication is low-dose aspirin. Vital signs are within normal limits. Physical examination reveals an erythematous, edematous left lower extremity with tenderness to palpation along the popliteal fossa. Her leg is warm, and distal pulses are palpable. Venous duplex ultrasonography confirms an occlusive thrombus in the left popliteal vein. Laboratory testing shows a normal complete blood count, normal serum creatinine, and a normal hepatic panel. Which of the following is the most appropriate pharmacologic intervention for managing this patient's acute thrombosis?

  1. Initiation of therapeutic enoxaparin with concurrent initiation of warfarinAnswer
  2. B
    Initiation of rivaroxaban monotherapy
  3. C
    Initiation of therapeutic enoxaparin followed by dabigatran in 5 days
  4. D
    Addition of clopidogrel to the current aspirin regimen
  5. E
    Intravenous tissue plasminogen activator followed by unfractionated heparin

Answer

Initiation of therapeutic enoxaparin with concurrent initiation of warfarin
The correct pharmacologic intervention for an acute deep vein thrombosis in a patient with antiphospholipid syndrome (APS) is a parenteral anticoagulant (such as low-molecular-weight heparin) bridged to a vitamin K antagonist (warfarin). This patient's history of arterial thrombosis (stroke), recurrent miscarriages, and the presence of all three APS antibodies (lupus anticoagulant, anti-cardiolipin, anti-beta-2-glycoprotein I) classifies her as having 'triple-positive' APS. While direct oral anticoagulants (DOACs) are currently the standard of care for typical venous thromboembolism in the general population, randomized clinical trials (such as the TRAPS trial) have demonstrated that DOACs are associated with a significantly higher rate of recurrent thrombosis—particularly arterial events—compared to warfarin in patients with APS. Consequently, all DOACs are strongly contraindicated in this specific patient population.

Step-by-Step Solution

1
Diagnose the acute presentation.
The patient has an acute, uncomplicated unprovoked deep vein thrombosis (DVT) in the setting of a known underlying prothrombotic state.
Ultrasound confirms a popliteal DVT, which requires immediate therapeutic anticoagulation.
2
Identify the patient's underlying coagulopathy from her medical history.
The patient has 'triple-positive' antiphospholipid syndrome (APS), indicated by her history of stroke, recurrent miscarriages, and positivity for all three classic autoantibodies.
Antiphospholipid syndrome profoundly alters the algorithm for selecting an appropriate anticoagulant.
3
Determine the optimal pharmacologic agent while screening for contraindications.
Direct oral anticoagulants (DOACs) are strictly contraindicated in triple-positive APS due to an increased risk of recurrent thromboembolic events.
Clinical trials (such as the TRAPS trial) demonstrated that DOACs fail to prevent recurrent arterial thromboses in APS compared to traditional vitamin K antagonists.
4
Select the guideline-concordant regimen.
The correct intervention is bridging with a parenteral agent (such as enoxaparin) to a vitamin K antagonist (warfarin).
Warfarin requires several days to reach therapeutic levels and can initially induce a transient prothrombotic state, necessitating a parenteral bridge.

Key Concept

Direct oral anticoagulants (DOACs) are contraindicated in patients with antiphospholipid syndrome (particularly triple-positive disease) due to an increased risk of recurrent thromboembolic events; these patients must be treated with a parenteral anticoagulant bridged to warfarin.
Estimated Time:1m 30s
Rate this question

Topics

Pharmacologic Interventions

More questions from this topic